TCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials September 26, 2014
TCL Archive Finasteride Cut Risk Of Prostate Cancer In Large Trial, But Value In Clinic Unclear. June 27, 2003